Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2021 | Molecular profiling of esophagogastric cancer patient-derived xenografts

Yelena Y. Janjigian • 11 Jan 2021
ASCO GI 2021
Gastric Cancer Gastrointestinal Cancer

Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, outlines the results of comprehensive molecular profiling of esophagogastric cancer patient-derived xenografts which were found to accurately recapitulate the genomic heterogeneity and tumor biology of patients with esophagogastric cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Yelena Y. Janjigian

1:34
DESTINY-Gastric03: T-DXd in HER2+ and HER2-low gastric cancer
Yelena Y. Janjigian • 19 Jan 2024
1:10
KEYNOTE-811: HRQOL pembro plus tras and chemo in first-line HER2+ advanced gastric cancer
Yelena Y. Janjigian • 19 Jan 2024
3:09
MATTERHORN: improved pCR with the use of durvalumab + FLOT in resectable GC/GEJC
Yelena Y. Janjigian • 19 Jan 2024
2:56
Perioperative immunotherapy and surgery for treating MSI-high esophagogastric tumors
Yelena Y. Janjigian • 3 Apr 2023

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals